HomeCompareVGREF vs MRK

VGREF vs MRK: Dividend Comparison 2026

VGREF yields 692.28% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VGREF wins by $829123.35M in total portfolio value
10 years
VGREF
VGREF
● Live price
692.28%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$829123.41M
Annual income
$645,656,795,042.41
Full VGREF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — VGREF vs MRK

📍 VGREF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVGREFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VGREF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VGREF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VGREF
Annual income on $10K today (after 15% tax)
$58,843.89/yr
After 10yr DRIP, annual income (after tax)
$548,808,275,786.05/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, VGREF beats the other by $548,808,267,189.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VGREF + MRK for your $10,000?

VGREF: 50%MRK: 50%
100% MRK50/50100% VGREF
Portfolio after 10yr
$414561.73M
Annual income
$322,828,402,578.09/yr
Blended yield
77.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VGREF
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VGREF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVGREFMRK
Forward yield692.28%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$829123.41M$57.7K
Annual income after 10y$645,656,795,042.41$10,113.78
Total dividends collected$814237.51M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VGREF vs MRK ($10,000, DRIP)

YearVGREF PortfolioVGREF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$79,928$69,228.11$11,213$373.04+$68.7KVGREF
2$602,651$517,128.18$12,667$512.06+$590.0KVGREF
3$4,288,859$3,644,021.75$14,439$708.14+$4.27MVGREF
4$28,825,743$24,236,664.30$16,640$988.16+$28.81MVGREF
5$183,083,222$152,239,676.79$19,432$1,394.07+$183.06MVGREF
6$1,099,573,723$903,674,675.23$23,057$1,992.90+$1099.55MVGREF
7$6,248,834,638$5,072,290,754.82$27,889$2,894.79+$6248.81MVGREF
8$33,626,094,931$26,939,841,868.20$34,518$4,286.29+$33626.06MVGREF
9$171,464,126,496$135,484,204,920.01$43,912$6,494.35+$171464.08MVGREF
10$829,123,410,393$645,656,795,042.41$57,714$10,113.78+$829123.35MVGREF

VGREF vs MRK: Complete Analysis 2026

VGREFStock

VIASPACE Green Energy Inc., a renewable energy company, manufacture and sells framed artwork in the United States. It operates through two segments, Framed-Artwork and Grass. The Framed-Artwork segment manufactures copyrighted framed artwork in the People's Republic of China for retail stores. The Grass Segment produces Giant King Grass, a natural hybrid, non-genetically modified, and perennial grass, which is used to generate low carbon and renewable electricity by burning in a biomass power plant; used to produce bio methane through anaerobic digestion; used as a feedstock for non-food liquid biofuels, such as bio ethanol and bio butanol; and used as a feedstock for biochemicals and bio plastics, as well as used as animal feed. The company was founded in 2008 and is headquartered in Marietta, Georgia.

Full VGREF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VGREF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VGREF vs SCHDVGREF vs JEPIVGREF vs OVGREF vs KOVGREF vs MAINVGREF vs JNJVGREF vs ABBVVGREF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.